Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

In UK patients hospitalised with COVID-19, high-titre convalescent plasma did not reduce 28-day mortality or other prespecified clinical outcomes vs usual care (n=11558; mortality rate 24% for both groups; RR 1.00; 95% CI 0.93–1.07; p=0.95).

The Lancet